Mark Plavsic
Known title: Chief Technical OfficerCIK: 0001868719
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Transaction History
| AURA | ▲ Buy | Grant | 62,339 | $0 | 3/2/2026 | View on chart |
| AURA | ▼ Sell | Open Market | 15,890 | $80K | 2/17/2026 | View on chart |
| AURA | ▼ Sell | Open Market | 12,169 | $77K | 10/16/2025 | View on chart |
| AURA | ▼ Sell | Open Market | 2,151 | $17K | 2/18/2025 | View on chart |
| AURA | ▲ Buy | Grant | 90,475 | $0 | 2/3/2025 | View on chart |
| AURA | ▼ Sell | Open Market | 7,383 | $73K | 10/16/2024 | View on chart |
| FATE | ▼ Sell | Open Market | 3,418 | $18K | 1/10/2023 | View on chart |
| FATE | ▼ Sell | Open Market | 3,719 | $92K | 7/5/2022 | View on chart |
| FATE | ▲ Buy | Grant | 33,302 | $0 | 1/25/2022 | View on chart |
| FATE | ▲ Buy | Grant | 59,540 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Aura Biosciences Announces Conference Participation and Inducement Grants
Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.
Aura Biosciences Announces Conference Participation and Inducement Grants. Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.